High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints

被引:379
|
作者
Lisio, Michael-Antony [1 ]
Fu, Lili [1 ]
Goyeneche, Alicia [1 ]
Gao, Zu-hua [1 ]
Telleria, Carlos [1 ]
机构
[1] McGill Univ, Dept Pathol, Expt Pathol Unit, Montreal, PQ H3A 2B4, Canada
关键词
high-grade serous ovarian cancer; cortical inclusion cysts; serous tubular intra-epithelial carcinoma; ovarian surface epithelium; homologous recombination; BRCA; mutant p53; genetically-engineered mouse models; debulking surgery; chemotherapy; TUBAL INTRAEPITHELIAL CARCINOMA; OLAPARIB MAINTENANCE THERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; GROSS RESIDUAL DISEASE; RANDOMIZED PHASE-III; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; OPEN-LABEL; TP53; MUTATIONS; DOUBLE-BLIND;
D O I
10.3390/ijms20040952
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Among a litany of malignancies affecting the female reproductive tract, that of the ovary is the most frequently fatal. Moreover, while the steady pace of scientific discovery has fuelled recent ameliorations in the outcomes of many other cancers, the rates of mortality for ovarian cancer have been stagnant since around 1980. Yet despite the grim outlook, progress is being made towards better understanding the fundamental biology of this disease and how its biology in turn influences clinical behaviour. It has long been evident that ovarian cancer is not a unitary disease but rather a multiplicity of distinct malignancies that share a common anatomical site upon presentation. Of these, the high-grade serous subtype predominates in the clinical setting and is responsible for a disproportionate share of the fatalities from all forms of ovarian cancer. This review aims to provide a detailed overview of the clinical-pathological features of ovarian cancer with a particular focus on the high-grade serous subtype. Along with a description of the relevant clinical aspects of this disease, including novel trends in treatment strategies, this text will inform the reader of recent updates to the scientific literature regarding the origin, aetiology and molecular-genetic basis of high-grade serous ovarian cancer (HGSOC).
引用
收藏
页数:33
相关论文
共 50 条
  • [41] Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients
    Zheng Feng
    Hao Wen
    Rui Bi
    Yachen Duan
    Wentao Yang
    Xiaohua Wu
    BMC Cancer, 16
  • [42] Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer
    Cardillo, Nicholas
    Devor, Eric J.
    Pedra Nobre, Silvana
    Newtson, Andreea
    Leslie, Kimberly
    Bender, David P.
    Smith, Brian J.
    Goodheart, Michael J.
    Gonzalez-Bosquet, Jesus
    CANCERS, 2022, 14 (14)
  • [43] Role of integrins in the metastatic spread of high-grade serous ovarian cancer
    Slavomir Krajnak
    Jörg Jäkel
    Katharina Anić
    Roxana Schwab
    Marcus Schmidt
    Annette Hasenburg
    Wilfried Roth
    Walburgis Brenner
    Marco Johannes Battista
    Archives of Gynecology and Obstetrics, 2022, 305 : 1291 - 1298
  • [44] High-grade serous ovarian cancer (HGSOC) with fallopian tube involvement
    Tanase, Adina Elena
    Solomon-condriuc, Iustina Petra
    Mogos, Raluca Anamaria
    Costachescu, Gabriel
    David, Cristina
    Buzduga, Catalin Mihai
    Scripcariu, Dragos Viorel
    Costea, Claudia Florida
    Cucu, Andrei Ionut
    Tanase, Gabriel Valentin
    Tanase, Daniela Maria
    Nemescu, Dragos
    Dumitrescu, Ana Maria
    Carauleanu, Alexandru
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2024, 65 (02): : 325 - 329
  • [45] KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
    De Donato, Marta
    Babini, Gabriele
    Mozzetti, Simona
    Buttarelli, Marianna
    Ciucci, Alessandra
    Arduini, Gloria
    De Rosa, Maria Cristina
    Scambia, Giovanni
    Gallo, Daniela
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [46] BRCA TESTING IN KAZAKHSTANI WOMEN WITH HIGH-GRADE SEROUS OVARIAN CANCER
    Satanova, Alima
    Kaidarova, Dilyara
    Bolatbekova, Raikhan
    Kukubassov, Yerlan
    Madina, Orazgaliyeva
    Ossikbayeva, Saniya
    Kurmanova, Anar
    Aydarov, Askar
    Bertleuov, Orynbassar
    Kaldybekov, Dauren
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A132 - A132
  • [47] Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer
    Al-Dossary, Amal A.
    Tawfik, Essam A.
    Isichei, Adaugo C.
    Sun, Xin
    Li, Jiahe
    Alshehri, Abdullah A.
    Alomari, Munther
    Almughem, Fahad A.
    Aldossary, Ahmad M.
    Sabit, Hussein
    Almalik, Abdulaziz M.
    CANCERS, 2021, 13 (12)
  • [48] KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
    Marta De Donato
    Gabriele Babini
    Simona Mozzetti
    Marianna Buttarelli
    Alessandra Ciucci
    Gloria Arduini
    Maria Cristina De Rosa
    Giovanni Scambia
    Daniela Gallo
    Journal of Experimental & Clinical Cancer Research, 39
  • [49] Role of tumor location on high-grade serous ovarian cancer prognosis
    Ay, Seval
    Ozyukseler, Deniz Tataroglu
    Basak, Mustafa
    Dulgar, Ozgecan
    Arici, Serdar
    Yildirim, Mahmut Emre
    Gumus, Mahmut
    GINEKOLOGIA POLSKA, 2022, 93 (04) : 284 - 289
  • [50] Credentialing ERalpha as target in high-grade serous ovarian cancer.
    Oesterreich, Steffi
    Anderson, Courtney L.
    Sikora, Matthew J.
    Boisen, Michelle M.
    Ma, Tianzhou
    Tseng, George
    Chandran, Uma
    Christie, Alec
    Park, Yongseok
    Luthra, Soumya
    Haluska, Paul
    Mantia-Smaldone, Gina
    Odunsi, Kunle
    McLean, Karen
    Lee, Adrian
    Ellshaev, Esther
    Edwards, Robert P.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 122 - 122